Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows – operating activities:
Net loss	$ (7)	$ (31)
Non-cash items –
Share-based plans expense	161	135
Treasury shares issued for 401(k) contributions	466	418
Depreciation and amortization	573	466
Investment/asset impairment charges, net	9	7
(Gain)/loss on dispositions, net	(12)	3
Other charges and credits, net	45	99
Changes in assets and liabilities –
Accounts receivable	(509)	(570)
Unbilled receivables	(635)	(671)
Advances and progress billings	3,181	781
Inventories	(2,634)	(1,521)
Other current assets	(418)	(29)
Accounts payable	1,073	(95)
Accrued liabilities	(1,260)	(386)
Income taxes receivable, payable and deferred	(16)	26
Other long-term liabilities	(49)	(151)
Pension and other postretirement plans	(22)	(150)
Financing receivables and operating lease equipment, net	(156)	12
Other	31	41
Net cash used by operating activities	(179)	(1,616)
Cash flows – investing activities:
Payments to acquire property, plant and equipment	(1,275)	(674)
Proceeds from disposals of property, plant and equipment	2	3
Contributions to investments	(9,265)	(8,797)
Proceeds from investments	16,256	7,750
Supplier notes receivable	(3)
Other	(4)	1
Net cash provided/(used) by investing activities	5,711	(1,717)
Cash flows – financing activities:
New borrowings	24	29
Debt repayments	(6,950)	(295)
Employee taxes on certain share-based payment arrangements	(31)	(14)
Dividends paid on mandatory convertible preferred stock	(86)	(72)
Other	15	14
Net cash used by financing activities	(7,028)	(338)
Effect of exchange rate changes on cash and cash equivalents	1	12
Net decrease in cash & cash equivalents, including restricted	(1,495)	(3,659)
Cash & cash equivalents, including restricted, at beginning of year	11,663	13,822
Cash & cash equivalents, including restricted, at end of period	10,168	10,163
Less restricted cash & cash equivalents, included in Investments	727	21
Cash and cash equivalents at end of period	$ 9,441	$ 10,142